Not Yet Recruiting
A Randomized, Open Label, Parallel Group Phase 1 Study to Compare Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MK-1406 as Three Injections Compared With Two Injections in Healthy Adult Participants
Led by Merck Sharp & Dohme LLC · Updated on 2026-08-03
400
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.
CONDITIONS
Brief Title
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Is in good health
- Has body mass index (BMI) 18.0 to 32.0 kg/m^2
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- History of cancer (malignancy)
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here